Season 2 (2021-2030)

Metabolic - Discovery (29)

Modality Indication Targets Stage Company Project No. Detail
1 Drug Development for NASH and obesity
Peptide NASH CXCR7 Hit Yonsei University HN22C0645
2 Exercise-induced myokine CLCF1, a novel potential treatment for sarcopenia
Recombinant Protein Sarcopenia CLCF1 Hit Korea Research Institute of Bioscience and Biotechnology HN22C0330
3 Treatment of NASH using autophagy enhancer ameliorateing organelle stress
Small Molecules NASH TFEB Hit LysoTech HN22C0278
4 Developing treatment for metabolic disease targeting PPARγ phosphorylation based on adipocyte remodeling
Small Molecules Diabetes, Obesity PPARγ S273 Hit Korea Research Institute of Bioscience and Biotechnology HN22C0120
5 Discovery of hit and lead compounds based on oral IP6 kinase inhibition to treat obesity
Small Molecules Obesity IP6K Hit Korea Advanced Institute of Science and Technology HN21C1265
6 Development of PAK4 inhibitor as anti-diabetes drug
Small Molecules Diabetes PAK4 Hit Jeonbuk National University HN21C0447
7 Development of lead compounds as a sphingomyelin synthase 1 inhibitor to reduce the hepatocyte lipotoxicity for the treatment of liver cirrhosis
Small Molecules Cirrhosis SMS1 Hit Seoul National University HN21C1150
8 Development of HIT compounds of MLKL inhibitors for treatment of nonalcoholic fatty liver disease
Small Molecules NASH MLKL Hit Hanyang University HN21C1149
9 Development of lead for intestinal glucotonic therapeutics based on atypical PKC activation for treatment of metabolic syndrome
Small Molecules Diabetes, Obesity Atypical PKC Hit Yonsei University HN21C1008
10 Development of peptide T against sarcopenia in a form of muscle-specific delivered fusion peptides
Peptide Sarcopenia TLQP21 Hit Asan Medical Center HN21C0976
11 Lead compound generation of DYRK1B inhibitor for NASH treatment
Small Molecules Liver fibrosis DYRK1B Lead Therasid Bioscience Inc. RS-2023-00283399
12 Discovery of lead compounds based on increase of lipolysis and energy expenditure to treat obesity
Small Molecules Obesity ALK7 Lead Gachon University RS-2023-00282576
13 Development of BKCa Channel Agonism Based New Drug Lead Compounds for Overactive Bladder Symptom
Small Molecules Bladder disease BKCa Lead GIST RS-2023-00258812
14 Development of STK25 inhibitor for treatment of nonalcoholic steatohepatitis
Small Molecules NASH STK25 Lead Korea Research Institute of Chemical Technology RS-2023-00218351
15 Lead discovery and development of production process for 
sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism
Recombinant Protein Sarcopenia NOTCH1 Lead NUON Bio RS-2022-00165803
16 Drug development for Duchenne muscular dystrophy by increasing mRNA stability
Small Molecules Duchenne muscular dystrophy NMD Lead RiboTech HN22C0723
17 Discovery of dual A2A adeosine receptor agonist/A3 adenosine antagonist as anti-obesity drug
Small Molecules Obesity A2AAR, A3AR Lead Seoul National University HN22C0687
18 Development of peripheral cannabinoid 1 receptor antagonists targeting diabetes and metabolic disease using AI/CADD-based technology
Small Molecules Diabetes CB1R Lead Sungkyunkwan University HN22C0203
19 Development of a PPAR/AMPK dual agonist for treatment of diabetes and metabolic syndrome
Small Molecules Diabetes PPARγ, AMPA Lead Seoul National University Hospital HN21C0497
20 Development of Lead compounds as a Deubiquitinase USP1 Inhibitor for Non-Alcoholic Fat Liver Diseases Therapy
Small Molecules NASH USP1 Lead Yonsei University HN21C0153
21 Fat-targeting non-viral gene therapeutics for the treatment of obesity and obesity-induced metabolic syndrome
Gene Therapy Obesity FABP4, FABP5 Lead Hanyang University HN21C0885
22 A Study on the Hit to Lead Optimization of Resistin Targeting Antibodies as a Treatment for Non-Alcoholic Fatty Liver Disease
Antibody NASH Resistin, CAP1 Lead Seoul National University Hospital HN21C0524
23 Research on lead optimization of miRNA-based therapeutics for treatment of sarcopenia
Gene Therapy Sarcopenia Atrogin-1 Lead Aventi Inc. HN21C0500
24 Development of Treatment Drugs for Obesity using Concomitant Administration of Microbiome Consortia
Others Obesity Bacteroides vulgatus, Roseburia intestinalis, Akkermansia muciniphila Candidate KoBiolabs Inc. RS-2023-00219249
25 Development of KARS1-target drug candidate with broad and high efficacy for treatment of NASH (non-alcoholic steatohepatitis)
Small Molecules NASH KARS1 Candidate Zymedi RS-2023-00218823
26 Establishing of Fc-flagellin-based candidate drug (MSP-306) for NASH treatment and entering non-clinical trials
Recombinant Protein NASH TLR5 Candidate MediSpan HN22C0599
27 A study on derivation and optimization of non-clinical candidates for nonalcoholic steatohepatitis gene therapy
Gene Therapy NASH CR-P1 Candidate Curogen Technology HN21C0805
28 Development of a preclinical candidate of a UniStac-based long-acting tetra-specific drug for NASH
Recombinant Protein NASH FGF21, GLP-1, GCG, a-cytokine Candidate Onegene Biotechnology Inc. HN21C0561
29 Development of long-acting human growth hormone receptor antagonist by next generation technology
Recombinant Protein Acromegaly hGH receptor Candidate Alteogen Inc. HN21C0535
BACK